<!DOCTYPE html>
<html lang="en" dir="ltr">
    <head>
        <meta charset="utf-8">
        <link rel="stylesheet" href="/static/rendered_html/uslm.css">
        <link rel="stylesheet" href="/static/rendered_html/style.css">
        <script src="https://kit.fontawesome.com/2ce1080035.js" crossorigin="anonymous"></script>
        <script lang="text/javascript" src="/static/rendered_html/omni.js" defer></script>

        <!-- Table of Contents button section sheet. Would ideally be a working breadcrumb --> 
        <img src="../omni.jpg" alt="Omnibuster" style="width:100%">
        <ul class="breadcrumb" style="text-align:center">
            <!-- TODO GENERALIZE THIS --> 
            <li><a href="index.html"> Table of Contents</a></li>
            
                <li> Division I </a></li>
            
                <li> Section 90004 </a></li>
            
        </ul>


        <!-- <title> Omnibuster </title>
 -->
    </head>

    <body>
        <br><br><br>
        <div class="section">
            <div class="buttons">
                <div class="navbar">
                    <div>
                        <button onclick="highlightSelection();">Highlight Text</button>
                    </div>
                    <div>
                        <button onclick="annotateSelection();">[Not working] Annotate Text</button>
                    </div> 
                </div>
            </div>
            <p> 
                <section id="d7367e157724" identifier="/us/bill/117/hr/3684/dI/s90004" role="instruction" style="-uslm-lc:I650145"><num value="90004">SEC. 90004. </num><heading>REQUIRING MANUFACTURERS OF CERTAIN SINGLE-DOSE CONTAINER OR SINGLE-USE PACKAGE DRUGS PAYABLE UNDER PART B OF THE MEDICARE PROGRAM TO PROVIDE REFUNDS WITH RESPECT TO DISCARDED AMOUNTS OF SUCH DRUGS.</heading>
<chapeau class="indent0 fontsize10" style="-uslm-lc:I650120">  Section 1847A of the Social Security Act (<a href="https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title42-section1395w–3a&amp;num=0&amp;edition=prelim" target="_blank"><ref href="/us/usc/t42/s1395w–3a">42 U.S.C. 1395w–3a</ref></a>) <amendingAction type="amend">is amended</amendingAction>—</chapeau><paragraph class="indentUp1 fontsize10" id="d7367e157737" identifier="/us/bill/117/hr/3684/dI/s90004/1" style="-uslm-lc:I650122"><num style="-uslm-lc:emspace2" value="1">(1) </num><content>by <amendingAction type="redesignate">redesignating</amendingAction> subsection (h) as subsection (i); and</content>
</paragraph>
<paragraph class="indentUp1 fontsize10" id="d7367e157747" identifier="/us/bill/117/hr/3684/dI/s90004/2" style="-uslm-lc:I650122"><num style="-uslm-lc:emspace2" value="2">(2) </num><content>by <amendingAction type="insert">inserting</amendingAction> after subsection (g) the following new subsection:<quotedContent><subsection class="indent0 fontsize10" style="-uslm-lc:I650120"><num style="-uslm-lc:emspace2" value="h">“(h) </num><heading><inline class="smallCaps">Refund for Certain Discarded Single-dose Container or Single-use Package Drugs</inline>.—</heading><paragraph class="indentUp1 fontsize10" style="-uslm-lc:I650122"><num style="-uslm-lc:emspace2" value="1">“(1) </num><heading><inline class="smallCaps">Secretarial provision of information</inline>.—</heading><subparagraph class="indentUp1 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="A">“(A) </num><heading><inline class="smallCaps">In general</inline>.—</heading><chapeau>For each calendar quarter beginning on or after January 1, 2023, the Secretary shall, with respect to a refundable single-dose container or single-use package drug (as defined in paragraph (8)), report to each manufacturer (as defined in subsection (c)(6)(A)) of such refundable single-dose container or single-use package drug the following for the calendar quarter:</chapeau><clause class="indentUp1 fontsize10" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="i">“(i) </num><content>Subject to subparagraph (C), information on the total number of units of the billing and payment code of such drug, if any, that were discarded during such quarter, as determined using a mechanism such as the JW modifier used as of the date of enactment of this subsection (or any such successor modifier that includes such data as determined appropriate by the Secretary).</content>
</clause>
<clause class="indentUp1 fontsize10" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="ii">“(ii) </num><content>The refund amount that the manufacturer is liable for pursuant to paragraph (3).</content>
</clause>
</subparagraph>
<subparagraph class="indentUp1 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="B">“(B) </num><heading><inline class="smallCaps">Determination of discarded amounts</inline>.—</heading><content>For purposes of subparagraph (A)(i), with respect to a refundable single-dose container or single-use package drug furnished during a quarter, the amount of such drug that was discarded shall be determined based on the amount of such drug that was unused and discarded for each drug on the date of service.</content>
</subparagraph>
<subparagraph class="indentUp1 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="C">“(C) </num><heading><inline class="smallCaps">Exclusion of units of packaged drugs</inline>.—</heading><content>The total number of units of the billing and payment code of a refundable single-dose container or single-use package drug of a manufacturer furnished during a calendar quarter for purposes of subparagraph (A)(i), and the determination of the estimated total allowed charges for the drug in the quarter for purposes of paragraph (3)(A)(ii), shall not include such units that are packaged into the payment amount for an item or service and are not separately payable.</content>
</subparagraph>
</paragraph>
<paragraph class="indentUp1 fontsize10" style="-uslm-lc:I650122"><num style="-uslm-lc:emspace2" value="2">“(2) </num><heading><inline class="smallCaps">Manufacturer requirement</inline>.—</heading><content>For each calendar quarter beginning on or after January 1, 2023, the manufacturer of a refundable single-dose container or single-use package drug shall, for such drug, provide to the Secretary a refund that is equal to the amount specified in paragraph (3) for such drug for such quarter.</content>
</paragraph>
<paragraph class="indentUp1 fontsize10" style="-uslm-lc:I650122"><num style="-uslm-lc:emspace2" value="3">“(3) </num><heading><inline class="smallCaps">Refund amount</inline>.—</heading><subparagraph class="indentUp1 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="A">“(A) </num><heading><inline class="smallCaps">In general</inline>.—</heading><chapeau>The amount of the refund specified in this paragraph is, with respect to a refundable single-dose container or single-use package drug of a manufacturer assigned to a billing and payment code for a calendar quarter beginning on or after January 1, 2023, an amount equal to the estimated amount (if any) by which—</chapeau><clause class="indentUp1 fontsize10" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="i">“(i) </num><chapeau>the product of—</chapeau><subclause class="indentUp1 fontsize10" style="-uslm-lc:I650128"><num style="-uslm-lc:emspace2" value="I">“(I) </num><content>the total number of units of the billing and payment code for such drug that were discarded during such quarter (as determined under paragraph (1)); and</content>
</subclause>
<subclause class="indentUp1 fontsize10" style="-uslm-lc:I650128"><num style="-uslm-lc:emspace2" value="II">“(II)</num><item class="inline"><num value="aa">(aa) </num><content>in the case of a refundable single-dose container or single-use package drug that is a single source drug or biological, the amount of payment determined for such drug or biological under subsection (b)(1)(B) for such quarter; or</content>
</item>
<item class="indent0 fontsize10" style="-uslm-lc:I650128"><num style="-uslm-lc:emspace2" value="bb">“(bb) </num><content>in the case of a refundable single-dose container or single-use package drug that is a biosimilar biological product, the amount of payment determined for such product under subsection (b)(1)(C) for such quarter; exceeds</content>
</item>
</subclause>
</clause>
<clause class="indentUp1 fontsize10" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="ii">“(ii) </num><content>an amount equal to the applicable percentage (as defined in subparagraph (B)) of the estimated total allowed charges for such drug under this part during the quarter.</content>
</clause>
</subparagraph>
<subparagraph class="indentUp1 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="B">“(B) </num><heading><inline class="smallCaps">Applicable percentage defined</inline>.—</heading><clause class="indentUp1 fontsize10" role="definitions" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="i">“(i) </num><heading><inline class="smallCaps">In general</inline>.—</heading><chapeau>For purposes of subparagraph (A)(ii), the term ‘<term>applicable percentage</term>’ means—</chapeau><subclause class="indentUp1 fontsize10" style="-uslm-lc:I650128"><num style="-uslm-lc:emspace2" value="I">“(I) </num><content>subject to subclause (II), 10 percent; and</content>
</subclause>
<subclause class="indentUp1 fontsize10" style="-uslm-lc:I650128"><num style="-uslm-lc:emspace2" value="II">“(II) </num><content>if applicable, in the case of a refundable single-dose container or single-use package drug described in clause (ii), a percentage specified by the Secretary pursuant to such clause.</content>
</subclause>
</clause>
<clause class="indentUp1 fontsize10" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="ii">“(ii) </num><heading><inline class="smallCaps">Treatment of drugs that have unique circumstances</inline>.—</heading><content>In the case of a refundable single-dose container or single-use package drug that has unique circumstances involving similar loss of product as that described in paragraph (8)(B)(ii), the Secretary, through notice and comment rulemaking, may increase the applicable percentage otherwise applicable under clause (i)(I) as determined appropriate by the Secretary.</content>
</clause>
</subparagraph>
</paragraph>
<paragraph class="indentUp1 fontsize10" style="-uslm-lc:I650122"><num style="-uslm-lc:emspace2" value="4">“(4) </num><heading><inline class="smallCaps">Frequency</inline>.—</heading><content>Amounts required to be refunded pursuant to paragraph (2) shall be paid in regular intervals (as determined appropriate by the Secretary).</content>
</paragraph>
<paragraph class="indentUp1 fontsize10" style="-uslm-lc:I650122"><num style="-uslm-lc:emspace2" value="5">“(5) </num><heading><inline class="smallCaps">Refund deposits</inline>.—</heading><content>Amounts paid as refunds pursuant to paragraph (2) shall be deposited into the Federal Supplementary Medical Insurance Trust Fund established under section 1841.</content>
</paragraph>
<paragraph class="indentUp1 fontsize10" style="-uslm-lc:I650122"><num style="-uslm-lc:emspace2" value="6">“(6) </num><heading><inline class="smallCaps">Enforcement</inline>.—</heading><subparagraph class="indentUp1 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="A">“(A) </num><heading><inline class="smallCaps">Audits</inline>.—</heading><clause class="indentUp1 fontsize10" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="i">“(i) </num><heading><inline class="smallCaps">Manufacturer audits</inline>.—</heading><content>Each manufacturer of a refundable single-dose container or single-use package drug that is required to provide a refund under this subsection shall be subject to periodic audit with respect to such drug and such refunds by the Secretary.</content>
</clause>
<clause class="indentUp1 fontsize10" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="ii">“(ii) </num><heading><inline class="smallCaps">Provider audits</inline>.—</heading><content>The Secretary shall conduct periodic audits of claims submitted under this part with respect to refundable single-dose container or single-use package drugs in accordance with the authority under section 1833(e) to ensure compliance with the requirements applicable under this subsection.</content>
</clause>
</subparagraph>
<subparagraph class="indentUp1 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="B">“(B) </num><heading><inline class="smallCaps">Civil money penalty</inline>.—</heading><clause class="indentUp1 fontsize10" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="i">“(i) </num><heading><inline class="smallCaps">In general</inline>.—</heading><chapeau>The Secretary shall impose a civil money penalty on a manufacturer of a refundable single-dose container or single-use package drug who has failed to comply with the requirement under paragraph (2) for such drug for a calendar quarter in an amount equal to the sum of—</chapeau><subclause class="indentUp1 fontsize10" style="-uslm-lc:I650128"><num style="-uslm-lc:emspace2" value="I">“(I) </num><content>the amount that the manufacturer would have paid under such paragraph with respect to such drug for such quarter; and</content>
</subclause>
<subclause class="indentUp1 fontsize10" style="-uslm-lc:I650128"><num style="-uslm-lc:emspace2" value="II">“(II) </num><content>25 percent of such amount.</content>
</subclause>
</clause>
<clause class="indentUp1 fontsize10" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="ii">“(ii) </num><heading><inline class="smallCaps">Application</inline>.—</heading><content>The provisions of section 1128A (other than subsections (a) and (b)) shall apply to a civil money penalty under this subparagraph in the same manner as such provisions apply to a penalty or proceeding under section 1128A(a).</content>
</clause>
</subparagraph>
</paragraph>
<paragraph class="indentUp1 fontsize10" style="-uslm-lc:I650122"><num style="-uslm-lc:emspace2" value="7">“(7) </num><heading><inline class="smallCaps">Implementation</inline>.—</heading><content>The Secretary shall implement this subsection through notice and comment rulemaking.</content>
</paragraph>
<paragraph class="indentUp1 fontsize10" style="-uslm-lc:I650122"><num style="-uslm-lc:emspace2" value="8">“(8) </num><heading><inline class="smallCaps">Definition of refundable single-dose container or single-use package drug</inline>.—</heading><subparagraph class="indentUp1 fontsize10" role="definitions" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="A">“(A) </num><heading><inline class="smallCaps">In general</inline>.—</heading><content>Except as provided in subparagraph (B), in this subsection, the term ‘<term>refundable single-dose container or single-use package drug</term>’ means a single source drug or biological (as defined in section 1847A(c)(6)(D)) or a biosimilar biological product (as defined in section 1847A(c)(6)(H)) for which payment is made under this part and that is furnished from a single-dose container or single-use package.</content>
</subparagraph>
<subparagraph class="indentUp1 fontsize10" role="definitions" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="B">“(B) </num><heading><inline class="smallCaps">Exclusions</inline>.—</heading><chapeau>The term ‘<term>refundable single-dose container or single-use package drug</term>’ does not include—</chapeau><clause class="indentUp1 fontsize10" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="i">“(i) </num><content>a drug or biological that is either a radiopharmaceutical or an imaging agent;</content>
</clause>
<clause class="indentUp1 fontsize10" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="ii">“(ii) </num><content>a drug or biological approved by the Food and Drug Administration for which dosage and administration instructions included in the labeling require filtration during the drug preparation process, prior to dilution and administration, and require that any unused portion of such drug after the filtration process be discarded after the completion of such filtration process; or</content>
</clause>
<clause class="indentUp1 fontsize10" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="iii">“(iii) </num><content>a drug or biological approved by the Food and Drug Administration on or after the date of enactment of this subsection and with respect to which payment has been made under this part for fewer than 18 months.</content>
</clause>
</subparagraph>
</paragraph>
<paragraph class="indentUp1 fontsize10" style="-uslm-lc:I650122"><num style="-uslm-lc:emspace2" value="9">“(9) </num><heading><inline class="smallCaps">Report to congress</inline>.—</heading><content>Not later than 3 years after the date of enactment of this subsection, the Office of the Inspector General, after consultation with the Centers for Medicare &amp; Medicaid Services and the Food and Drug Administration, shall submit to the Committee on Finance of the Senate and the Committee on Energy and Commerce and the Committee on Ways and Means of the House of Representatives, a report on any impact this section is reported to have on the licensure, market entry, market retention, or marketing of biosimilar biological products. Such report shall be updated periodically at the direction of the Committee on Finance of the Senate and the Committee on Energy and Commerce and the Committee on Ways and Means of the House of Representatives.”</content>
</paragraph>
</subsection>
</quotedContent>.</content>
</paragraph>
</section>
            </p>
        </div>  

        <!-- previous section -->
        <button onclick="location.href='section_s90003.html'" id="ls-btn-prev-sec" title="go to previous section">
            <i class="fas fa-angle-left"></i>
        </button>
        <!-- end previous section -->

        <!-- next section -->
        <button onclick="location.href='section_s90005.html'" id="ls-btn-next-sec" title="go to next section" data-ls-target-index="2">
            <i class="fas fa-angle-right"></i>
        </button>
        <!-- end next section -->

    </body>
